Cargando…

Non-myeloablative busulfan chimeric mouse models are less pro-inflammatory than head-shielded irradiation for studying immune cell interactions in brain tumours

BACKGROUND: Chimeric mouse models generated via adoptive bone marrow transfer are the foundation for immune cell tracking in neuroinflammation. Chimeras that exhibit low chimerism levels, blood-brain barrier disruption and pro-inflammatory effects prior to the progression of the pathological phenoty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Youshani, A. Saam, Rowlston, Samuel, O’Leary, Claire, Forte, Gabriella, Parker, Helen, Liao, Aiyin, Telfer, Brian, Williams, Kaye, Kamaly-Asl, Ian D., Bigger, Brian W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362590/ https://www.ncbi.nlm.nih.gov/pubmed/30722781 http://dx.doi.org/10.1186/s12974-019-1410-y

Ejemplares similares

A nonmyeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma
por: Yu, K., et al.
Publicado: (2018)

High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma
por: Yu, Kenny Kwok-Hei, et al.
Publicado: (2018)

Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC
por: O’Leary, Claire, et al.
Publicado: (2023)

Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated Ex Vivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA
por: Ellison, Stuart M., et al.
Publicado: (2019)

Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
por: Bremer, Sara, et al.
Publicado: (2015)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
por: Zhu, Shengyun, et al.
Publicado: (2021)

Improved engraftment and therapeutic efficacy by human genome-edited hematopoietic stem cells with Busulfan-based myeloablation
por: Poletto, Edina, et al.
Publicado: (2022)

Correction: The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
Publicado: (2022)

Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
por: Gleitz, Hélène FE, et al.
Publicado: (2018)

Preclinical IV busulfan dose-finding study to induce reversible myeloablation in a non-human primate model
por: Mahmud, Nadim, et al.
Publicado: (2018)

Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children
por: Benadiba, Joy, et al.
Publicado: (2018)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

Melatonin and Testicular Damage in Busulfan Treated Mice
por: Mirhoseini, Mehri, et al.
Publicado: (2014)

Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
por: Bonifazi, Francesca, et al.
Publicado: (2022)

Production of germline chimeric quails following spermatogonial cell transplantation in busulfan-treated testis
por: Kim, Young Min, et al.
Publicado: (2018)

P1270: MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES
por: Popat, Uday R., et al.
Publicado: (2023)

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity
por: Stephens, Sarah J., et al.
Publicado: (2016)

Signal One and Two Blockade Are Both Critical for Non-Myeloablative Murine HSCT across a Major Histocompatibility Complex Barrier
por: Langford-Smith, Kia J., et al.
Publicado: (2013)

Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation
por: Byun, Hwa Kyung, et al.
Publicado: (2017)

Phase I trial of myeloablative conditioning with 3‐day total marrow and lymphoid irradiation for leukemia
por: Ogawa, Hiroaki, et al.
Publicado: (2022)

Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II
por: Gleitz, Hélène F. E., et al.
Publicado: (2017)

Bone Marrow T Cells are Superior to Splenic T Cells to Induce Chimeric Conversion After Non-Myeloablative Bone Marrow Transplantation
por: Park, Hyun-Sil, et al.
Publicado: (2009)

Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy
por: Guidolin, Valeria, et al.
Publicado: (2023)

Haematopoietic stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA
por: Parker, Helen, et al.
Publicado: (2020)

Comparison of gamma and x-ray irradiation for myeloablation and establishment of normal and autoimmune syngeneic bone marrow chimeras
por: Wittenborn, Thomas Rea, et al.
Publicado: (2021)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Pulmonary hypertension associated with busulfan
por: Hagenburg, Jean, et al.
Publicado: (2021)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation
por: Goh, Ri-Young, et al.
Publicado: (2011)

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15
por: Hell, Saskia, et al.
Publicado: (2022)

Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling
por: McCune, Jeannine S., et al.
Publicado: (2022)

Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies
por: Hirabayashi, Koichi, et al.
Publicado: (2014)

Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy
por: Farhan, Shatha, et al.
Publicado: (2017)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Awake brain surgery for autistic patients: Is it possible?
por: Drosos, Evangelos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_et9juv52u04ncs8tip096338eq